Literature DB >> 25100730

Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.

Tadashi Yoshida1, Maho Yamashita2, Chihiro Horimai2, Matsuhiko Hayashi2.   

Abstract

Kruppel-like factor 4 (KLF4) plays an important role in vascular diseases, including atherosclerosis and vascular injury. Although KLF4 is expressed in the heart in addition to vascular cells, the role of KLF4 in cardiac disease has not been fully determined. The goals of this study were to investigate the role of KLF4 in cardiac hypertrophy and to determine the underlying mechanisms. Cardiomyocyte-specific Klf4 knockout (CM Klf4 KO) mice were generated by the Cre/LoxP technique. Cardiac hypertrophy was induced by chronic infusion of the β-adrenoreceptor agonist isoproterenol (ISO). Results showed that ISO-induced cardiac hypertrophy was enhanced in CM Klf4 KO mice compared with control mice. Accelerated cardiac hypertrophy in CM Klf4 KO mice was accompanied by the augmented cellular enlargement of cardiomyocytes as well as the exaggerated expression of fetal cardiac genes, including atrial natriuretic factor (Nppa). Additionally, induction of myocardin, a transcriptional cofactor regulating fetal cardiac genes, was enhanced in CM Klf4 KO mice. Interestingly, KLF4 regulated Nppa expression by modulating the expression and activity of myocardin, providing a mechanical basis for accelerated cardiac hypertrophy in CM Klf4 KO mice. Moreover, we showed that KLF4 mediated the antihypertrophic effect of trichostatin A, a histone deacetylase inhibitor, because ISO-induced cardiac hypertrophy in CM Klf4 KO mice was attenuated by olmesartan, an angiotensin II type 1 antagonist, but not by trichostatin A. These results provide novel evidence that KLF4 is a regulator of cardiac hypertrophy by modulating the expression and the activity of myocardin.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Adrenergic Receptor; Angiotensin II; Cardiac Hypertrophy; Natriuretic Peptide; Serum Response Factor; Transcription Factor

Mesh:

Substances:

Year:  2014        PMID: 25100730      PMCID: PMC4176239          DOI: 10.1074/jbc.M114.582809

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Left ventricular hypertrophy: pathogenesis, detection, and prognosis.

Authors:  B H Lorell; B A Carabello
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

Review 2.  MicroRNAs in control of cardiac hypertrophy.

Authors:  Paula A Da Costa Martins; Leon J De Windt
Journal:  Cardiovasc Res       Date:  2012-01-19       Impact factor: 10.787

3.  Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.

Authors:  Akira Ido; Naoyuki Hasebe; Toshiharu Takeuchi; Kenjiro Kikuchi
Journal:  J Cardiovasc Pharmacol       Date:  2003-01       Impact factor: 3.105

4.  Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes.

Authors:  Tadashi Yoshida; Sanjay Sinha; Frédéric Dandré; Brian R Wamhoff; Mark H Hoofnagle; Brandon E Kremer; Da-Zhi Wang; Eric N Olson; Gary K Owens
Journal:  Circ Res       Date:  2003-03-27       Impact factor: 17.367

5.  Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3.

Authors:  Vinciane Gaussin; Tom Van de Putte; Yuji Mishina; Mark C Hanks; An Zwijsen; Danny Huylebroeck; Richard R Behringer; Michael D Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

6.  Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.

Authors:  Liza Barki-Harrington; Louis M Luttrell; Howard A Rockman
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

7.  Forced expression of myocardin is not sufficient for induction of smooth muscle differentiation in multipotential embryonic cells.

Authors:  Tadashi Yoshida; Keiko Kawai-Kowase; Gary K Owens
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

8.  Myocardin is a master regulator of smooth muscle gene expression.

Authors:  Zhigao Wang; Da-Zhi Wang; G C Teg Pipes; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

9.  Myocardin mRNA is augmented in the failing myocardium: expression profiling in the porcine model and human dilated cardiomyopathy.

Authors:  Mario Torrado; Eduardo López; Alberto Centeno; Constancio Medrano; Alfonso Castro-Beiras; Alexander T Mikhailov
Journal:  J Mol Med (Berl)       Date:  2003-08-13       Impact factor: 4.599

10.  The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon.

Authors:  Jonathan P Katz; Nathalie Perreault; Bree G Goldstein; Catherine S Lee; Patricia A Labosky; Vincent W Yang; Klaus H Kaestner
Journal:  Development       Date:  2002-06       Impact factor: 6.868

View more
  22 in total

Review 1.  Regulation of cardiac myocyte cell death and differentiation by myocardin.

Authors:  Joseph W Gordon
Journal:  Mol Cell Biochem       Date:  2017-06-19       Impact factor: 3.396

2.  Hyperglycemia induces vascular smooth muscle cell dedifferentiation by suppressing insulin receptor substrate-1-mediated p53/KLF4 complex stabilization.

Authors:  Gang Xi; Xinchun Shen; Christine Wai; Morris F White; David R Clemmons
Journal:  J Biol Chem       Date:  2018-12-21       Impact factor: 5.157

3.  The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1.

Authors:  Xiao-Jun Feng; Hui Gao; Si Gao; Zhuoming Li; Hong Li; Jing Lu; Jiao-Jiao Wang; Xiao-Yang Huang; Min Liu; Jian Zou; Jian-Tao Ye; Pei-Qing Liu
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

Review 4.  Kruppel-like factors in muscle health and disease.

Authors:  Domenick A Prosdocimo; M Khaled Sabeh; Mukesh K Jain
Journal:  Trends Cardiovasc Med       Date:  2014-11-15       Impact factor: 6.677

5.  Expression characteristics and functional analysis of Krüppel-like factor 4 in adductor muscle and mantle of Zhikong scallop Chlamys farreri.

Authors:  Dandan Yang; Shaoshuai Liang; Qiankun Yang; Danwen Liu; Zhenkui Qin; Zhifeng Zhang
Journal:  Dev Genes Evol       Date:  2018-03-03       Impact factor: 0.900

6.  Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.

Authors:  Madhu V Singh; Michael Z Cicha; Sarah Nunez; David K Meyerholz; Mark W Chapleau; François M Abboud
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-22       Impact factor: 4.733

7.  Modulation of cardiac fibrosis by Krüppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes.

Authors:  Daigo Sawaki; Lianguo Hou; Shota Tomida; Junqing Sun; Hong Zhan; Kenichi Aizawa; Bo-Kyung Son; Taro Kariya; Eiki Takimoto; Kinya Otsu; Simon J Conway; Ichiro Manabe; Issei Komuro; Scott L Friedman; Ryozo Nagai; Toru Suzuki
Journal:  Cardiovasc Res       Date:  2015-05-17       Impact factor: 10.787

Review 8.  Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.

Authors:  Tadashi Yoshida; Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2016-06-13       Impact factor: 2.801

9.  Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.

Authors:  Jonathan W Nelson; Mohammed Z Ferdaus; James A McCormick; Jessica Minnier; Sanjiv Kaul; David H Ellison; Anthony P Barnes
Journal:  Physiol Genomics       Date:  2018-01-08       Impact factor: 3.107

10.  Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'.

Authors:  Stefanie Maria Werhahn; Julia S Kreusser; Marco Hagenmüller; Jan Beckendorf; Nathalie Diemert; Sophia Hoffmann; Jobst-Hendrik Schultz; Johannes Backs; Matthias Dewenter
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.